NCT05643677

Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer

Fruquintinib Plus Irinotecan Second-line Treatment for Advanced Gastric Cancer: a Single-arm, Open-label, Singer-center, Phase II Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 47 (estimated)
• Sponsor: Fujian Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study explores the efficacy and safety of fruquintinib combined with irinotecan in the second-line treatment of patients with advanced gastric cancer, aiming to bring more second-line treatment options for patients with advanced gastric cancer.

Detailed description

This study was a single-arm, open-label, single-center phase II study. A total of 47 patients with advanced gastric cancer who had previously failed standard first-line therapy were recruited to receive combined treatment with fruquintinib and irinotecan. The patients' progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety were evaluated.

Conditions

• Gastric Cancer

Interventions

Type	Name	Description
DRUG	Fruquintinib	4 mg PO, QD (3 weeks on, 1 week off)
DRUG	Irinotecan	participants will receive irinotecan, 100 mg/m2, intravenous drip, day1 and day 14 of every 4 weeks

Timeline

• Start date: 2022-12-01
• Primary completion: 2024-11-01
• Completion: 2025-11-01
• First posted: 2022-12-09
• Last updated: 2022-12-09